The Vanguard Group, Inc. recently announced the acquisition of new stake in Cardlytics Inc (NASDAQ:CDLX). The institutional investor has increased its shareholding in the Communication Services company by 13.14% to 1.98 million shares with purchase of 0.23 million shares. This fresh investment now brings its stake to 5.05% valued currently at $18.25 million. In addition, Worldly Partners Management LLC raised its holdings by 18592.0 to 1.0 million shares. And Invesco Capital Management LLC has lifted its position by 538.07% or 0.68 million shares – to 0.8 million shares.
Currently, there are 39.25M common shares owned by the public and among those 36.32M shares have been available to trade.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Insiders at the company have transacted a total of 43 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 26 of these insider trades were purchases, accounting for 598,877 shares. Insider sales of the common stock occurred on 17 occasions, with total insider shares sold totaling 270,455 shares.
The top 3 mutual fund holders in Cardlytics Inc are Vanguard Total Stock Market ETF, iShares Russell 2000 ETF, and Vanguard Extended Market Index Fu. Vanguard Total Stock Market ETF owns 1.14 million shares of the company’s stock, all valued at over $10.54 million. iShares Russell 2000 ETF sold 2628.0 shares to see its total holdings shrink to 0.99 million shares valued at over $9.11 million and representing 2.52% of the shares outstanding. Vanguard Extended Market Index Fu bought 30316.0 shares to bring its total holdings to over 0.57 million shares at a value of $5.27 million. Vanguard Extended Market Index Fu now owns shares totaling to 1.46% of the shares outstanding.
The company’s stock has a 5-day price change of 8.94% and -38.76% over the past three months. CDLX shares are trading -21.93% year to date (YTD), with the 12-month market performance up to 12.70% higher. It has a 12-month low price of $2.57 and touched a high of $19.57 over the same period. CDLX has an average intraday trading volume of 744.22K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 1.83%, -7.83%, and -25.28% respectively.
Institutional ownership of Cardlytics Inc (NASDAQ: CDLX) shares accounts for 71.24% of the company’s 39.25M shares outstanding. Mutual fund holders own 28.33%, while other institutional holders and individual stakeholders account for 50.34% and 20.94% respectively.
It has a market capitalization of $282.21M and a beta (3y monthly) value of 1.32. The earnings-per-share (ttm) stands at -$12.25. Price movements for the stock have been influenced by the stock’s volatility, which stands at 9.61% over the week and 7.02% over the month.
Analysts forecast that Cardlytics Inc (CDLX) will achieve an EPS of $0.06 for the current quarter, -$0.24 for the next quarter and -$0.14 for 2024. The lowest estimate earnings-per-share for the quarter is -$0.01 while analysts give the company a high EPS estimate of $0.14. Comparatively, EPS for the current quarter was -$0.29 a year ago. Earnings per share for the fiscal year are expected to increase by 90.95%, and -32.54% over the next financial year. EPS should grow at an annualized rate of 44.10% over the next five years, compared to -47.93% over the past 5-year period.
Looking at the support for the CDLX, a number of firms have released research notes about the stock. Lake Street stated their Buy rating for the stock in a research note on November 29, 2023, with the firm’s price target at $13.
